World experts join University’s biomedical program

23 June 2015

The University’s biomedical engineering undergraduate program will receive student and research support from industry experts with the appointment of two adjunct professors - Drs Steven Farrugia and Jeffrey Armitstead.

Professor Archie Johnston, dean of Engineering and Information Technologies at the University says there has been exponential growth in the undergraduate biomedical program making it the largest undergraduate program in Australia.

“The faculty has also developed a track record for excellence in research in image processing and data management, bioinformatics, medical devices and networking, biomaterials and regenerative tissue engineering,” the dean said.

The appointment of Drs Farrugia and Armitstead will assist the faculty in continuing its leadership position in biomedical education and research.

Dr Farrugia who is recognised as is a world expert on positive pressure therapeutic devices has a track record of leading new product development projects, from concept through to commercialisation.

An alumnus of the University and Vice President (Technology) with ResMed, Dr Farrugia has said:

“I am passionate about biomedical engineering, the future of manufacturing in Australia (in particular the role of the medical device industry) and the critical importance of science, technology, engineering and mathematics (STEM) education to Australia's continued prosperity.”

His colleague Dr Armitstead also a ResMed Vice President has extensive clinical trial experience for both devices and respiratory masks including protocol development, project management and statistical analysis. He also comes from a strong academic background lecturing in the fields of sleep, respiratory medicine and bioengineering.

An internationally published researcher and principal author of several patents, Dr Armitstead says:

“I'm passionate about changing the world through research, invention, applied technology and the mentoring of others.”

About ResMed
The global team at ResMed is united in their commitment to changing lives with every breath. With more than 4,000 employees and a presence in 100 countries, the company has been pioneering new and innovative devices and treatments for sleep-disordered breathing, chronic obstructive pulmonary disease, and other key chronic diseases for more than 25 years. ResMed's world-leading products and innovative solutions improve the quality of life for millions of patients worldwide, reduce the impact of chronic disease, and save healthcare costs.

Media enquiries:
Victoria Hollick, 0401 711 361 or